Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Defense Tech ETF (SHLD) vs TransMedics Group Inc (TMDX) Price & Performance

Global X Defense Tech ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Global X Defense Tech ETF vs TransMedics Group Inc — how do they compare? Global X Defense Tech ETF trades at $70.11, while TransMedics Group Inc trades at $87.33 (market cap $3.10B). The key difference: Global X Defense Tech ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

SHLDTMDX
Sector
Sector/ThematicTechnology
52-Week High
$78.02$150.42
52-Week Low
$58.20$61.99
Market Cap
$3.10B
Enterprise Value
$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Defense Tech ETF

SHLD, the Global X Defense Tech ETF, trades at $69.74, down slightly by 0.16% today. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI levels suggest overbought conditions. Recent news highlights increased institutional investment, with firms like Focus Financial Network raising stakes by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF benefits from global defense spending trends, including a $20 billion UK military overhaul (Zacks Investment Research, 2026-07-02).

The outlook for SHLD is positive, driven by rising global defense budgets and technological advancements in defense sectors. Investment opportunities include diversified exposure to defense innovation, supported by institutional accumulation. Risks involve geopolitical shifts, potential tariff impacts from policies like Trump's new tariffs (Fool - Investing News, 2026-08-04), and valuation pressures if growth slows. The ETF's performance hinges on sustained military expenditure increases and contract awards.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

About Global X Defense Tech ETF

SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.

Read more on SHLD

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX